← Back

Wire · founder news, decoded · opportunities

Cervical disc device outperforms fusion in FDA trial

Published

21 July 2026

Topic

opportunities

Sectors

Digital Health

Geography

United States

Source

Read at beckersspine.com

Verified

Fusion42 · 21 July 2026 · Fusion42 review

Synergy Spine's Synergy Disc, a motion-preserving cervical disc replacement device, reached 100 implants in 100 days following FDA approval and demonstrated clinical superiority to fusion in its IDE trial with an 87.1% success rate at 24 months.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.

The Wire takeaway

If you supply materials, tooling or manufacturing for cervical implants, Synergy just proved the market will abandon fusion for motion-preserving devices—and Medtronic, Stryker and Zimmer now have a validated competitive threat to protect market share. Call your spine surgeon customers this week to understand which procedures they're converting.

Related on Wire

Topics

Digital Health · fda-approval · spinal-surgery · device-adoption · fusion-displacement · motion-preservation